A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Teratogenicity The teratogenic effects of aflatoxin B1 in rabbits have been reported to include reduced fetal weights, wrist drop, enlarged eye socket, agenesis of caudal vertebrae, micropthalmia, cardiac defects, and lenticular degeneration, among others. Immunotoxicity Studies in fish showed aflatoxin B1 to have significant immunosuppressive effects including reduced serum total globulin and reduced bactericidal activities.
Diminished memory: In a 2015 article, researchers re-analyzing results from the 1999–2005 UCSD Statin Study argue that "greater dietary trans fatty acid consumption is linked to worse word memory in adults during years of high productivity." Acne: According to a 2015 study, trans fats are one of several components of Western pattern diets which promote acne, along with carbohydrates with high glycemic load such as refined sugars or refined starches, milk and dairy products, and saturated fats, while omega-3 fatty acids, which reduce acne, are deficient in Western pattern diets.
=== 2 September === Thirteen people were killed in an SAF drone strike on a market in Mellit. The SAF-aligned government said that it would continue to open the Adre border crossing with Chad until the end of the year.
== Dangers == Scarification produces harm and trauma to the skin. Infection is common when tools are not sterilised properly. Scarification has been linked to the spread of HIV/AIDS and Hepatitis C when tools are shared between people. Body modification artists may have less experience with scarification, perhaps due to lower demand. When not desired, keloid scars may be an additional complication, although there are emerging treatment strategies for them.
Larkin, Colin (1992). The Guinness Who's Who of Indie and New Wave Music. Guinness Publishing. ISBN 0-85112-579-4. Lazell, Barry (1997). Indie Hits 1980-1989. Cherry Red Books. ISBN 0-9517206-9-4. Robertson, John (1988). The Jesus and Mary Chain – a Musical Biography. Omnibus Press. ISBN 0-7119-1470-2. Strong, Martin C. (2003). The Great Indie Discography. Canongate. ISBN 1841953350. Taylor, Steve (2004). The A to X of Alternative Music. Continuum International Publishing Group Ltd. ISBN 978-0-8264-7396-7. Thompson, Dave (2000). Alternative Rock. Miller Freeman Books. ISBN 0-87930-607-6. Wilson, Dave (2004). Rock Formations: Categorical Answers to How Band Names Were Formed. Cidermill Books. ISBN 0-9748483-5-2. Reid, William; Reid, Jim (2024). Never Understood: The Jesus and Mary Chain. Da Capo. ISBN 978-0306835513.
Sources: en.wikipedia.org
According to the 2010 census, 40.1% of Belizeans were Catholics, 31.8% Protestants (8.4% Pentecostal; 5.4% Adventist; 4.7% Anglican; 3.7% Mennonite; 3.6% Baptist; 2.9% Methodist; 2.8% Nazarene), 1.7% were Jehovah's Witnesses, 10.3% adhered to other religions (Maya religion, Garifuna religion, Obeah and Myalism, and minorities of the Church of Jesus Christ of Latter-day Saints, Hindus, Buddhists, Muslims, Baháʼís, Rastafarians and other) and 15.5% professed to be irreligious.
==== Conservative Care ==== Back pain is generally first treated with nonpharmacological therapy, as it typically resolves without the use of medication. Superficial heat and massage, acupuncture and spinal manipulation therapy may be recommended. There is poor evidence for the effectiveness of most interventional treatments (drugs and surgery) for back pain and hence non-interventional treatments should be prioritized in the vast majority of cases.
It was first detected spectroscopically in late 1931 by Harold Urey, a chemist at Columbia University. Urey's collaborator, Ferdinand Brickwedde, distilled five liters of cryogenically produced liquid hydrogen to 1 mL of liquid, using the low-temperature physics laboratory that had recently been established at the National Bureau of Standards (now National Institute of Standards and Technology) in Washington, DC. The technique had previously been used to isolate heavy isotopes of neon. The cryogenic boiloff technique concentrated the fraction of the mass-2 isotope of hydrogen to a degree that made its spectroscopic identification unambiguous.
Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication containing serdexmethylphenidate, a prodrug of dexmethylphenidate, and dexmethylphenidate, a d-threo enantiomer of racemic methylphenidate, which is used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older. Side effects include decreased appetite, nausea, indigestion, weight loss, dizziness, mood swings, increased blood pressure, trouble sleeping, vomiting, stomach pain, anxiety, irritability, and increased heart rate. It was approved for medical use in the United States in March 2021.
Sources: en.wikipedia.org
Precursors to chemistry Alchemy (outline) History of alchemy History of the branches of chemistry History of analytical chemistry – history of the study of separation, identification, and quantification of the chemical components of natural and artificial materials. History of cosmochemistry – history of the study of the chemical composition of matter in the universe and the processes that led to those compositions History of atmospheric chemistry – history of the branch of atmospheric science in which the chemistry of the Earth's atmosphere and that of other planets is studied. It is a multidisciplinary field of research and draws on environmental chemistry, physics, meteorology, computer modeling, oceanography, geology and volcanology and other disciplines History of biochemistry – history of the study of chemical processes in living organisms, including, but not limited to, living matter. Biochemistry governs all living organisms and living processes. History of agrochemistry – history of the study of both chemistry and biochemistry which are important in agricultural production, the processing of raw products into foods and beverages, and in environmental monitoring and remediation. History of bioinorganic chemistry – history of the examination of the role of metals in biology. History of bioorganic chemistry – history of the rapidly growing scientific discipline that combines organic chemistry and biochemistry. History of biophysical chemistry – history of the new branch of chemistry that covers a broad spectrum of research activities involving biological systems.
== Radiation-induced hair loss == Radiation induces hair loss through damage to hair follicle stem cell progenitors and alteration of keratin expression. Radiation therapy has been associated with increased mucin production in hair follicles. Studies have suggested electromagnetic radiation as a therapeutic growth stimulant in alopecia.
=== Recording of examination === The patient's dentition is divided into six sextants – three sextants for the mandible and maxillary respectively. All teeth, except the 3rd molars, are examined (note the 3rd molars are included if there are no other molars in that sextant). The sextants include: Upper Right (17 to 14) Upper Anterior (13 to 23) Upper Left (24 to 27) Lower Right (47 to 44) Lower Anterior (43 to 33) Lower Left (34 to 37) For a sextant to be recorded, at least two teeth must be present. Otherwise, the lone standing tooth will be included with the recordings of the adjacent sextant.
Dehydration is a common risk factor for exertional rhabdomyolysis because it causes a reduction of plasma volume during exertion. This leads to a reduction of blood flow through the vascular system which inhibits blood vessel constriction.
The Egyptians were the first to produce an artificial imitation of turquoise, in the glazed earthenware product faience. Later glass and enamel were also used, and in modern times more sophisticated porcelain, plastics, and various assembled, pressed, bonded, and sintered products (composed of various copper and aluminium compounds) have been developed: examples of the latter include "Viennese turquoise", made from precipitated aluminium phosphate colored by copper oleate; and "neolith", a mixture of bayerite and copper(II) phosphate. Most of these products differ markedly from natural turquoise in both physical and chemical properties, but in 1972, Pierre Gilson introduced one fairly close to a true synthetic (it does differ in chemical composition owing to a binder used, meaning it is best described as a simulant rather than a synthetic). Gilson turquoise is made in both a uniform color and with black "spiderweb matrix" veining not unlike the natural Nevada material. The most common imitation of turquoise encountered today is dyed howlite and magnesite, both white in their natural states, and the former also having natural (and convincing) black veining similar to that of turquoise. Dyed chalcedony, jasper, and marble is less common, and much less convincing.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.